ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Retinal sublayer changes in cases with Alzheimer's disease and depression.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlzheimer's disease (AD) and depression are two prevalent conditions in the elderly population, both of which may impact the structure or function of the visual pathway. This study simultaneously investigated the effects of AD and depression on optic nerve head and macular parameters using Optical Coherence Tomography (OCT) imaging.
methodsThis cross-sectional study included two groups: 50 individuals with mild to moderate AD and 50 age-matched healthy controls (HCs). All participants underwent the Patient Health Questionnaire-9 (PHQ-9) and Mini-Mental State Examination (MMSE). Comprehensive ophthalmic examinations were performed, and individuals with significant refractive errors or ocular pathologies were excluded. Peripapillary RNFL (pRNFL) and macular layer imaging were conducted using Heidelberg OCT.
resultsCompared to HCs, AD patients showed significant thinning of pRNFL in the supra temporal (HC: 136.38 ± 17.68 μm vs. AD: 127.45 ± 16.08 μm, P = 0.010) and infra temporal (HC: 139.46 ± 20.88 μm vs. AD: 127.99 ± 17.06 μm, P = 0.003) quadrants, while temporal and nasal sectors were not significantly different. Inner macular layers were also significantly reduced in the AD group: GCL volume (1.043 ± 0.073 vs. 0.981 ± 0.083 mm³, P < 0.001), IPL volume (0.872 ± 0.061 vs. 0.834 ± 0.048 mm³, P = 0.001), and GCC (2.832 ± 0.181 vs. 2.671 ± 0.192 mm³, P < 0.001). Depression severity correlated negatively with GCL volume (ρ = - 0.260, P = 0.009). In stepwise regression analysis, MMSE score was more strongly associated with GCL volume than depression status and entered the model as the main predictor (β = 0.489, P < 0.001). The MMSE × depression interaction term was also significant (β = -0.213, P = 0.020), indicating that depression modified the association between cognitive impairment and GCL thinning.
conclusionsAD and depression in the elderly can influence the thickness of inner retinal layers, with dementia appearing to have a more pronounced effect than depression. These retinal changes may have important implications not only for the early diagnosis and monitoring of AD, but also for the accuracy of OCT-based detection of early glaucoma in patients with coexisting neuropsychiatric disorders-particularly in those with AD, where reliable visual field testing may also be challenging.
Indexed as
Identifiers
42417851What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.